Table 1

Baseline Clinical Characteristics and Changes in Several Variables at the Two-Week Interval

Sauna-Treated Group (n = 20)Nontreated Group (n = 10)Comparison atBaseline
BaselineAfter 2 Weeksp ValueBaselineAfter 2 WeeksP Valuep Value
Age (yrs)62 ± 1564 ± 160.74
Gender (M/F)12/86/41.0
DCM/ICM17/38/20.73
NYHA functional class (I/II/III)0/10/101/14/50.010/5/50/5/51.01.0
Body weight (kg)53.5 ± 12.353.3 ± 12.20.5260.8 ± 16.261.8 ± 15.60.420.18
SBP (mm Hg)107 ± 2297 ± 170.019112 ± 14111 ± 140.870.52
DBP (mm Hg)63 ± 1361 ± 100.4067 ± 667 ± 141.00.26
Heart rate (beats/min)71 ± 1370 ± 110.6168 ± 1467 ± 140.660.57
CTR (%)58.2 ± 7.155.9 ± 7.90.00256.2 ± 4.456.3 ± 4.50.590.42
LVEDD (mm)59 ± 857 ± 90.04760 ± 759 ± 80.420.74
LAD (mm)46 ± 945 ± 100.1741 ± 841 ± 80.180.15
Ejection fraction (%)38 ± 1439 ± 120.7832 ± 1331 ± 120.730.27
Norepinephrine (pg/ml)426 ± 234432 ± 3330.91464 ± 185467 ± 2590.970.66
Epinephrine (pg/ml)31 ± 3632 ± 340.9428 ± 1329 ± 190.840.74
Dopamine (pg/ml)12 ± 3011 ± 350.3114 ± 1314 ± 100.890.80
ANP (pg/ml)107 ± 10190 ± 940.34111 ± 104116 ± 1120.750.92
BNP (pg/ml)441 ± 444293 ± 3020.005434 ± 420454 ± 3960.640.97
TBARS (pg/ml)2.6 ± 1.12.6 ± 1.30.892.8 ± 0.93.0 ± 0.90.420.81
TNF-alpha (pg/ml)1.4 ± 0.81.6 ± 1.70.651.4 ± 1.81.3 ± 1.60.900.65
%FMD (%)4.4 ± 2.55.7 ± 2.50.00064.5 ± 1.94.4 ± 1.90.690.91
%NTG-induced dilation (%)19.2 ± 6.518.7 ± 6.90.6118.0 ± 5.417.1 ± 5.30.330.42
Hyperemia (%)478 ± 209417 ± 2610.20500 ± 325473 ± 1910.730.83

*Comparison with baseline values. Data are presented as the mean value ± SD.

ANP = atrial natriuretic peptide; BNP = brain natriuretic peptide; CTR = cardiothoracic ratio; DBP = diastolic blood pressure; %FMD = percent flow-mediated dilation; ICM = ischemic cardiomyopathy; DCM = dilated cardiomyopathy; LAD = left atrial dimension; LVEDD = left ventricular end-diastolic dimension; %NTG = percent nitroglycerin; NYHA = New York Heart Association; SBP = systolic blood pressure; TBARS = thiobarbituric acid-reactive substances; TNF-alpha = tumor necrosis factor-alpha.